3 results
Approved WMOCompleted
Primary:Cohort 1: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days isadministered to patients with ED-SCLC that haveplatinum-sensitive disease* Cohort 2: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days…
Approved WMORecruiting
To assess which treatment leads to the best patient outcome on the short term (1 year) and the long term (5 years)
Approved WMOCompleted
In this study we will investigate how safe the compound leriglitazone is and how well it is tolerated when it is used by healthy participants.Apart from extensive laboratory and animal testing, leriglitazone has been used in the past both in healthy…